Whitehawk Therapeutics (WHWK)

Overall impact
C (60)

Commentary

Whitehawk Therapeutics is an average overall performer. With a 'C' rating of 59.8 for overall impact (62nd percentile compared to all companies), Whitehawk Therapeutics ranks 496th out of 670 industry peers, behind Curium Pharma, Allena Pharmaceuticals, Pluristem Therapeutics and 492 others, and ahead of Madrigal Pharmaceuticals, Aldeyra Therapeutics, Aptose Biosciences and 171 others. On top material causes for Whitehawk Therapeutics's industry (Biotechnology), Whitehawk Therapeutics performs well in Child and Maternal Health (95.4 score), Child and Maternal Health (95.4), Child and Maternal Health (95.4) and 7 other causes where it received an 'A' score and performs poorly in Reduced Waste (18.5 score), Humane Treatment of Animals (21.9), Disaster Readiness and Effective Aid (21.1) and 5 other causes where it received a 'D' or 'F' score.
Impact
Cause WHWK
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
32
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Nj, United States
Share classes
WHWK
Description
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides a three-asset antibody-drug conjugate (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in March 2025. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
Material causes
Ethos considers the following causes material for Whitehawk Therapeutics, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.